Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer... Show more
A.I.dvisor indicates that over the last year, EXEL has been loosely correlated with INCY. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if EXEL jumps, then INCY could also see price increases.
| Ticker / NAME | Correlation To EXEL | 1D Price Change % | ||
|---|---|---|---|---|
| EXEL | 100% | -1.62% | ||
| INCY - EXEL | 54% Loosely correlated | -1.30% | ||
| MIRM - EXEL | 47% Loosely correlated | +1.33% | ||
| PTCT - EXEL | 43% Loosely correlated | -1.37% | ||
| ARQT - EXEL | 38% Loosely correlated | +4.52% | ||
| IMTX - EXEL | 38% Loosely correlated | -0.16% | ||
More | ||||
a developer of small molecule therapies for the treatment of cancer
Industry Biotechnology
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where EXEL advanced for three days, in 209 of 306 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
The Moving Average Convergence Divergence (MACD) for EXEL just turned positive on October 09, 2026. Looking at past instances where EXEL's MACD turned positive, the stock continued to rise in 29 of 43 cases over the following month. The odds of a continued upward trend are 67%.
The Aroon Indicator entered an Uptrend today. In 172 of 274 cases where EXEL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 63%.
The 10-day RSI Indicator for EXEL moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 40 similar instances where the indicator moved out of overbought territory. In 24 of the 40 cases, the stock moved lower in the following days. This puts the odds of a move lower at 60%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 39 of 75 cases where EXEL's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 52%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EXEL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 59%.
EXEL broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Profit vs. Risk Rating rating for this company is 3 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 23 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. EXEL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.349) is normal, around the industry mean (3.498). P/E Ratio (21.146) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (2.618) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (6.305) is also within normal values, averaging (440.869).